Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Global FFR as Prognosis in CAD Patients without Ischemia

Global fractional flow reserve (FFR) results from adding up FFR values of the three major coronary arteries. This figure represents the physiological atherosclerosis burden and can predict events at long term in patients without stenosis leading to ischemia.

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

This recent study published in JAHA looked at major cardiovascular events (death, infarction and revascularization) at 5 years in 1122 patients with no significant stenosis (lesions with FFR > 0.8 n=275) or presenting at least one significant lesion successfully treated (post PCI FFR > 0.8 n=847).

FFR was measured in the three main coronary arteries and these values were added to stratify patients into global FFR tertiles (low ≤ 2.80, intermediate between 2.80 and 2.88, and high ≥ 2.88).

Patients in the lowest tertile presented more events at 5 years compared against the intermediate and high tertiles (27.5% vs 22.0% and 20.9%, respectively; p=0.040).

The highest events rate in the group with low global FFR was driven mainly by more revascularization (16.4% vs 11.3% and 11.8%, respectively; p=0.038).


Read also: Sapien 3 Performs Well in “Jobs” for Which It Is Not Designed.


For each additional 0.1 FFR there was a significant reduction in total events (HR 0.988; CI 95%, 0.977 to 0.998; p=0.023), infarctions (HR 0.982; CI 95%, 0.966 to 0.998; p=0.032) and revascularization (HR 0.985; CI 95%, 0.972 to 0.999; p=0.040).

This is one of the studies that most clearly shows the concept of FFR as a continuous variable with a large spectrum of greys, as opposed to a binary variable below or over 0.8. 

Conclusion

Global FFR (the added FFR values of the three main cardiac arteries) is capable of predicting events at 5 years even in patients without ischemia driven by stenosis. Global FFR can be interpreted as the burden of physiological atherosclerosis.

JAHA-120-017729free

Original Title: Global Fractional Flow Reserve Value Predicts 5-Year Outcomes in Patients With Coronary Atherosclerosis But Without Ischemia.

Reference: Stephane Fournier et al. J Am Heart Assoc. 2020;9:e017729.  DOI: 10.1161/JAHA.120.017729.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...